Research of hepatoprotective melatonin properties and the role of polymorphism of the geme mtnr1b in patients with diabetes mellitus type 2

O. M. Oleshchuk, Ya. I. Ivankiv, O. A. Shumska

Abstract


 The application of melatonin to improve the treatment of patients with diabetes mellitus (DM) type 2, including hepatoprotective properties and its effect on carbohydrate metabolism were studied. It is established the relationship between gene polymorphism MT2 receptor, namely its variants: rs1387153 and rs10830963 and levels of fasting glucose and type 2 diabetes.


Keywords


melatonin; diabetes mellitus; liver.

References


Antonova O. I. Morfolohichni osoblyvosti pechinky pry nestachi melatoninu v riznykh umovakh / O. I. Antonova // Visn.k problem biolohii i medytsyny. – 2011. – Vyp. 2(2). – S. 14–16.

Antoniuk-Shchehlova I. A. Dosvid zastosuvannia melatoninu v litnikh khvorykh iz tsukrovym diabetom 2 typu / I. A. Antoniuk-Shchehlova // Endokrynolohiia. – 2013. – 18, № 4. – S. 32–38.

Arushanian E. B. Melatonin i sakharnyi diabet (obzor sovremennykh eksperimentalnykh dannykh) / E. B. Arushanian // Problemy endokrinologii. – 2012. – № 2. – S. 35–40.

Borisenok O. A. Biologicheskaia rol melatonina i ego klinicheskoe primenenie / O. A. Borisenok, K. M. Bushma // Meditcinskie novosti. – 2011. – № 1. – S. 26–29.

Kuznetcova E. I. Ispolzovanie melatonina v kachestve gepatoprotektora pri vnepechenochnom kholestaze / E. I. Kuznetcova, I. V. Semak // Biologiia – nauka XXI veka : 16-ia Mezhdunar. Pushch. shk.-konf. molodykh uchenykh (Pushchino, 16–21 apr. 2012 g.) : sb. tez. / Pushch. nauch. tcentr Ros. akad. nauk. – Pushchino, 2012. – S. 180–181.

Melatonin pri sakharnom diabete: ot patofiziologii k perspektivam lecheniia / V. I. Konenkov, V. V. Klimontov, S. V. Michurina [i dr.] // Sakharnyi diabet. – 2013. – № 2. – S. 11–16.

Melatonin: perspektivy primeneniia v klinike / pod. red. S. I. Rapoporta. – M. : IMA-PRESS, 2012. – S. 8–12.

Fediv O. I. Osoblyvosti urazhennia hepatobiliarnoi systemy u khvorykh na tsukrovyi diabet II typu / O. I. Fediv, Iu. F. Marchuk, L. O. Voloshyna // Bukovyn. med. visn. – 2008. – 12, № 4. – S. 126–131.Langenberg C. Common genetic variation in the melatonin receptor 1B gene (MTNR1B) isassociated with decreased early-phase insulin response /C. Langenberg, L. Pascoe // Diabetol. – 2009. – Vol.52. – P. 1537–1542.

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) / S. E. Inzucchi, R. M. Bergenstal, J. B. Buse [et al.] // Diabetes Care. – 2012. – Vol. 35(6). – P. 1364–1379.

Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients / K. Kedziora-Kornatowska, K. Szewczyk-Golec, M. Kozakiewicz [et al.] // J. Pineal Res. – 2009. – № 46. – Р. 333–337.

Relationship between melatonin receptor 1B (rs10830963 and rs1387153) with gestational diabetes mellitus: a case–control study and meta-analysis / Q. Liu, Z. Huang, H. Li // Arch Gynecol Obstet. – 2016. – Vol. 294, № 1. – Р. 55–61

Schmidt R. Hepatoprotective actions of melatonine: Possible mediation by melatonine receptors / R. Schmidt // World J Gastroenterol – 2010. – № 16 (48). – P. 6087–6097.

Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial / R. K. Simmons, J. B. Echouffo-Tcheugui, S. J. Sharp [et al.] // The Lancet. – 2012. – Vol. 380(9855). – P. 1741–1748.




DOI: http://dx.doi.org/10.11603/mcch.2410-681X.2016.v0.i4.7256

Refbacks

  • There are currently no refbacks.